Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Research and development	$ 30,914	$ 18,873
General and administrative	9,138	7,989
Total operating expenses	40,052	26,862
Loss from operations	(40,052)	(26,862)
Other income, net:
Interest income	2,300	2,651
Interest expense	(68)	(95)
Change in fair value of derivative liabilities	(1,650)
Other income, net	188	3
Total other income, net	770	2,559
Net loss	$ (39,282)	$ (24,303)
Net loss per share, basic	$ (0.59)	$ (0.64)
Net loss per share, diluted	$ (0.59)	$ (0.64)
Weighted average shares of common stock outstanding used to compute basic net loss per share	66,341,305	38,155,373
Weighted average shares of common stock outstanding, used to compute diluted net loss per share	66,341,305	38,155,373

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.